A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
复制标题
DOI：
10.1016/j.humpath.2009.06.019
复制
发表时间：
2010-01-01
期刊：
影响因子：
3.3
通讯作者：
Dacic, Sanja
中科院分区：
文献类型：
--
作者：
Monaco, Sara E.;Nikiforova, Marina N.;Dacic, Sanja
表皮生长因子受体（EGFR）和v-Ki-ras 2 （KRAS；病毒性Kirsten大鼠sacoma 2癌基因同源物）癌基因是肺癌对EGFR靶向治疗反应的预测因子。肺癌的形态学异质性反映在分子水平上，可能会混淆免疫组织化学、荧光原位杂交和突变分析的解释，这些都用于KRAS和EGFR基因的分析。此外，原发肿瘤和相应转移瘤的分子特征可能不同。本研究的目的是确定原发性和转移性肺癌的KRAS和/或EGFR状态是否不同。336例原发性肺癌进行了EGFR和KRAS检测，85例发生转移（25%）。在40例（47%）有足够材料进行EGFR和KRAS突变分析的病例中，有11例（27.5%）原发肿瘤和4例（10%）转移瘤被鉴定为KRAS突变。在EGFR荧光原位杂交结果的病例中，3例（8%）原发肿瘤和8例（24%）转移瘤荧光原位杂交阳性。总的来说，KRAS状态不一致9例（22.5%），EGFR荧光原位杂交状态不一致11例（32.5%）。我们的研究结果提示原发性肺癌的EGFR和KRAS状态可能不能预测相应转移的状态。这一观察结果可能对靶向治疗的分子检测具有重要意义。(c) 2010爱思唯尔公司版权所有。
Epidermal growth factor receptor (EGFR) and v-Ki-ras 2 (KRAS; viral Kirsten rat sacoma 2 oncogene homolog) oncogenes are predictors of response to EGFR-targeted therapy in lung carcinomas. Morphologic heterogeneity of lung carcinomas is reflected at the molecular level and may confound interpretation of immunohistochemistry, fluorescence in situ hybridization, and mutational assays, which are all used for analysis of KRAS and EGFR genes. Furthermore, molecular characteristics may differ between the primary tumor and corresponding metastases. The aim of this study was to determine if the KRAS and/or EGFR status of primary and metastatic lung carcinoma differs. Three hundred thirty-six cases of primary lung carcinomas were tested for EGFR and KRAS, and 85 cases had a metastasis (25%). Of the 40 cases (47%) with sufficient material for EGFR and KRAS mutational analysis, there were 11 (27.5%) primary tumors and 4 (10%) metastases identified with a KRAS mutation. Of the cases with EGFR fluorescence in situ hybridization results, there were 3 (8%) primary tumors and 8 (24%) metastases that were fluorescence in situ hybridization positive. Overall, there were 9 cases (22.5%) with discordant KRAS status and 11 cases (32.5%) with discordant EGFR fluorescence in situ hybridization status. Our results suggest that the EGFR and KRAS status of primary lung carcinomas may not predict the status in the corresponding metastases. This observation may have important implications for molecular testing for targeted therapies. (c) 2010 Elsevier Inc. All rights reserved.